Considering the lower blood glucose levels and β-cell size, along with the corresponding reduced insulin levels in the current CQR-300-treated group, it is speculated that CQR-300 may inhibit gluconeogenesis and prevent the worsening of insulin resistance in T2DM by reducing glucose-stimulated insulin secretion. This evidence concerns the gene INS and type 2 diabetes mellitus.